Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0WLYOR
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
MLN2704
|
|||||
| Synonyms |
MLN 591-DM1 conjugate; MLN 591-DM1; MLN 2704; MLN-2704; MLN2704
Click to Show/Hide
|
|||||
| Organization |
ImmunoGen, Inc.; Millennium Pharmaceuticals, Inc.; Takeda Pharmaceutical Co., Ltd.
|
|||||
| Drug Status |
Terminated in phase 2
|
|||||
| Indication |
In total 1 Indication(s)
Prostate cancer [ICD11:2C82]
Terminated in phase 2
|
|||||
| Drug-to-Antibody Ratio |
3-4
|
|||||
| Structure |
|
|||||
| Antibody Name |
MLN591
|
Antibody Info | ||||
| Antigen Name |
Glutamate carboxypeptidase 2 (FOLH1)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Thiopentanoate linker
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through nucleophilic lysines.
|
|||||
| Puchem SID | ||||||
| ChEBI ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.